Loading…
← CockpitCompetitor Analysis › AARTIDRUGS.NS Aarti Drugs LimitedOpen in the cockpit ↗

Aarti Drugs LimitedAARTIDRUGS.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Pharmaceuticals: Major
Momentum leader 93
Mkt cap
$494M
US dollars, full cap
Free float
40%
of shares outstanding
$/day
$12.5M
20-day average traded
Fwd P/E
21.3×
forward earnings
ROIC−WACC
-3.2 pp
WACC 13.4%
Hurdle
+19 pp
Req g minus delivered
Next earnings
70 days
27 Jan 2027
Close · INR₹505.75
1D+0.6%
1W+3.2%
1M+26.7%
3M+22.5%
6M+33.7%
YTD+22.9%
1Y+6.5%
ATR %4.3%
Beta0.70
52w lowhigh4.1% off high

What Aarti Drugs does

Employees: 2,831

Aarti Drugs at a glance

Size Aarti Drugs (AARTIDRUGS.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $494M, the 846th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹505.75 on 18 Nov 2026.

Performance Over six months the shares gained 33.7%, against -18.4% for the median peer and +3.8% for the India market (cap-weighted) — 5th highest of 21 in its peer set.

Growth Revenue grew 15.1% over the last twelve months (peer median +9.8%); the operating margin is 10.9% (peer median 10.0%).

Valuation It trades at 21.3× forward earnings against a peer median of 15.1× (2nd most expensive of 6).

Price implies For today's price to make sense, revenue must grow about 22% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is +19 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 3.2 points below its cost of capital (13.4% WACC).

Next results Next results expected around 27 Jan 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026AARTIDRUGS.NS 133Peer median 83
Six months, rebased to 100: Aarti Drugs against the median of its 20 peers (local-currency closes).

Aarti Drugs financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹28.5B₹25.6B₹23.8B₹25.2B₹27.2B
Revenue growth—+7%-6%-7%—
Gross profit₹8.75B₹3.72B₹3.46B₹3.64B₹3.69B
EBITDA₹3.84B₹3.06B₹2.87B₹3.20B₹3.15B
Net income₹2.29B₹1.95B₹1.68B₹1.71B₹1.66B
Free cash flown/a₹491M₹462M₹1.04B-₹661M
Capital expendituren/a₹1.73B₹1.77B₹2.26B₹1.65B
Total debt₹6.20B₹5.77B₹6.15B₹5.64B₹6.09B

Quarterly statements and history in the cockpit →

Aarti Drugs competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%0%+20%002107003090600513TKNO1666600222301277GYRE300584GUJTHEMINDPRGNXHNSAEGTX600624SMSPHARMAAARTIDRUGS.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Aarti Drugs is the large dot.

Fundamentals: revenue growth against valuation

-10%0%+10%+20%20×40×0030901666003020EGTXSMSPHARMAAARTIDRUGS.NSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Aarti Drugs is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%0%50%100%0021071666600222301277300584HNSAAARTIDRUGS.NSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Aarti Drugs is the large dot.

Aarti Drugs competitors and peer comparison

How Aarti Drugs compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Aarti Drugs against its 20 peers (data as of 18 Nov 2026)
MeasureAARTIDRUGS.NSPeer medianRank in peer set
1-month return+26.7%-2.1%highest of 21
6-month return+33.7%-18.4%5th highest of 21
Distance from 52-week high-4.1%-35.5%2nd highest of 21
Revenue growth (TTM)+15.1%+9.8%7th highest of 20
Operating margin10.9%10.0%10th highest of 20
Forward P/E21.3×15.1×2nd most expensive of 6
Growth the price implies (Req g, 7 yrs)22.1%-0.7%most demanding of 9
Growth delivered (Del g)+3.5%+7.0%3rd lowest of 9
Hurdle (Req g minus delivered)+18.6 pp-6.6 ppmost demanding of 9
ROIC minus cost of capital-3.2 pp-2.4 pp8th lowest of 18
EV / EBITDA13.6×15.3×3rd cheapest of 5
Net debt / EBITDA1.6×1.8×2nd least indebted of 5

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Aarti Drugs AARTIDRUGS.NSIndia$494M+34%+15%11%21.3×22.1%+3.5%
Shandong Wohua Pharmaceutical 002107.SZChina$493M-20%-4%18%n/a5.9%-4.1%
Daewoong 003090.KSSouth Korea$495M-28%+6%11%4.1×n/an/a
Jiangsu Lianhuan Pharmaceutical 600513.SSChina$496M-41%+14%0%n/an/an/a
Alpha Teknova TKNOUnited States$496M+113%+15%-32%n/an/an/a
Tong Ren Tang Technologies 1666.HKHong Kong$491M-19%-14%12%7.3×-17.2%+6.3%
Henan Taloph Pharmaceutical Stock 600222.SSChina$497M-21%-5%7%n/a16.7%+4.4%
Newland Pharmaceutical 301277.SZChina$488M-22%+9%11%n/a8.9%+9.1%
Gyre Therapeutics GYREUnited States$500M-28%+14%-18%n/an/an/a
Nanjing Hicin Pharmaceutical 300584.SZChina$487M-29%+32%17%n/a3.3%-1.1%
Hefei Lifeon Pharmaceutical 003020.SZChina$486M-21%-1%10%18.2×n/an/a
Shanghai Xiao Fang Pharmaceutical 603207.SSChina$503M-17%+10%39%n/a-5.4%+7.6%
Gujarat Themis Biosyn GUJTHEM.NSIndia$505M+2%+18%39%n/an/an/a
Indaptus Therapeutics INDPUnited States$505M+147%n/an/an/an/an/a
Shanghai MicuRx Pharmaceutical 688373.SSChina$481M-8%+23%-61%n/an/an/a
REGENXBIO RGNXUnited States$480M+22%-5%-120%n/an/an/a
Hansa Biopharma HNSA.STSweden$479M+39%+69%-190%n/a-4.7%+105.3%
Egetis Therapeutics EGTX.STSweden$509M+76%+27%-645%15.1×n/an/a
Shanghai Fudan Forward S&T 600624.SSChina$478M0%-14%-34%n/an/an/a
SMS Pharmaceuticals SMSPHARMA.NSIndia$477M+16%+13%16%42.2×n/an/a
Xizang Weixinkang Pharmaceutical 603676.SSChina$513M-22%-8%16%n/a-6.1%+9.6%

Questions

Which companies are Aarti Drugs's closest peers?
The cockpit's peer set: Shandong Wohua Pharmaceutical (002107.SZ), Daewoong (003090.KS), Jiangsu Lianhuan Pharmaceutical (600513.SS), Alpha Teknova (TKNO), Tong Ren Tang Technologies (1666.HK), Henan Taloph Pharmaceutical Stock (600222.SS), Newland Pharmaceutical (301277.SZ), Gyre Therapeutics (GYRE).
Is Aarti Drugs expensive compared with its peers?
On forward p/e it trades at 21.3× against a peer median of 15.1×, 2nd most expensive of 6 in its peer set. For today's price to make sense, revenue must grow about 22% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is +19 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Aarti Drugs stock performed?
Over six months to 18 Nov 2026 the shares returned +33.7% against -18.4% for the median peer; over one year +6.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.